相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
Jinheng Wang et al.
BLOOD (2014)
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen et al.
BLOOD (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
Massimo Martino et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
Annamaria Brioli et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial
M. Bhutani et al.
LEUKEMIA (2014)
Clonal evolution in hematological malignancies and therapeutic implications
D. A. Landau et al.
LEUKEMIA (2014)
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
B. A. Walker et al.
LEUKEMIA (2014)
Association of response endpoints with survival outcomes in multiple myeloma
S. Lonial et al.
LEUKEMIA (2014)
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
L. Melchor et al.
LEUKEMIA (2014)
Serial exome analysis of disease progression in premalignant gammopathies
S. Zhao et al.
LEUKEMIA (2014)
Pursuing the curative blueprint for early myeloma
Mark Roschewski et al.
BLOOD (2013)
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
Saad Z. Usmani et al.
BLOOD (2013)
Reply to Metronomic chemotherapy beyond misconceptions - Haematologica 2013; 98(11):e145
Xenofon Papanikolaou et al.
HAEMATOLOGICA (2013)
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
B. Paiva et al.
LEUKEMIA (2013)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Curability of Multiple Myeloma
Raymond Alexanian et al.
BONE MARROW RESEARCH (2012)
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
Christina M. Annunziata et al.
BLOOD (2011)
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
Philippe Moreau et al.
BLOOD (2011)
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Joaquin Martinez-Lopez et al.
BLOOD (2011)
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
Elena Zamagni et al.
BLOOD (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
Frits van Rhee et al.
BLOOD (2010)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Bart Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma
Marta Lionetti et al.
BLOOD (2009)
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
Antje Hoering et al.
BLOOD (2009)
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla B. Bartel et al.
BLOOD (2009)
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Ching-Hon Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Going with the flow, and beyond, in myeloma
Bart Barlogie et al.
BLOOD (2008)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
Mauricio Pineda-Roman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more
B. Barlogie et al.
LEUKEMIA (2008)
The Arkansas approach to therapy of patients with multiple myeloma
Bart Barlogie et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
Jeffrey Haessler et al.
CLINICAL CANCER RESEARCH (2007)
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Frits van Rhee et al.
BLOOD (2007)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications
Ronald Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan et al.
BLOOD (2007)
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
Mauricio Pineda-Roman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Cancer as an evolutionary and ecological process
Lauren M. F. Merlo et al.
NATURE REVIEWS CANCER (2006)
Tumor microenvironment and drug resistance hematologic malignancies
Zhi-Wei Li et al.
BLOOD REVIEWS (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cure of myeloma: hype or reality?
A Fassas et al.
BONE MARROW TRANSPLANTATION (2005)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
